Tumor Absorbed Dose-Response Relationship in Patients Treated With 177Lu-DOTATATE for Meningioma

The hypothesis for this study is that there is a dose-response relationship in patients treated with 177Lu-DOTATATE for meningiomas.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Meningioma of Brain Central Nervous System Neoplasms Meningeal Neoplasms Meningioma Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Nerve Tissue Neoplasms, Vascular Tissue Nervous System Diseases Nervous System Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHRU de NANCY, Vandœuvre-lès-Nancy, France

About this study

Dosimetry is essential for Peptide Receptor Radionuclide Therapy (PRRT) of meningiomas, to predict efficacy and dose-effect relationships at the individual level, and to move towards personalized medicine. Due to the increasing therapeutic applications of Lutathera, the European Association of Nuclear Medicine (EANM) recently issued recommendations on the dosimetry of 177Lu-labeled somatostatin analogues. Nevertheless, despite these recommendations, the evaluation of meningioma tumor dosimetry in Peptide Receptor Radionuclide Therapy studies is not systematic, which has not enabled us to clearly determine the dose delivered to the meningioma lesion in these treatments and the possible dose-response relationship in this type of treatment.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patients treated for menigioma at nancy hospital
patients who performed 3 scintigraphics exams during there treatment

Exclusion criteria

patients deprived of liberty
patient who refused to collect data retrospectively

Treatment and study plan

tumoral dosimetry by scintigraphy

Diagnostic Test

The tumoral dosimetry has been done on patient after treatment by 177Lu-DOTATATE Theses patients performed a scintigraphy exam at D1, D4 and D7 after the treatment

Primary outcomes

Diagnostic accuracy for progression free survival

Time frame: Day 1

Accuracy of tumor dosimetry to predict 6-month progression-free survival.

Secondary outcomes

Diagnostic accuracy for overal survival

Time frame: Day 1

Accuracy of tumoral dosimetry in predicting 6-month overall survival

Sponsors and collaborators

Lead sponsor

Central Hospital, Nancy, France

Other

Registry information

Acronym: DATUM

Important dates

Study start: 2024
Primary completion: 2025
Study completion: 2025
First posted: Sep 26, 2024
Registry last updated: Jun 25, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed